Cyclic AMP raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
== Personal life == In 2003, Laidlaw said his favorite games included the Legend of Zelda series, Animal Crossing, Um Jammer Lammy, Castlevania: Symphony of the Night, Ico, Fatal Frame and Thief: The Dark Project. After leaving Valve, Laidlaw moved to Kauai, Hawaii. He moved to Los Angeles in 2020. He has an amateur radio license and his call sign is WH6FXC. Laidlaw also writes and records music.
Estradiol can be taken by a variety of different routes of administration. These include oral, buccal, sublingual, intranasal, transdermal (gels, creams, patches), vaginal (tablets, creams, rings, suppositories), rectal, by intramuscular or subcutaneous injection (in oil or aqueous), and as a subcutaneous implant. The pharmacokinetics of estradiol, including its bioavailability, metabolism, biological half-life, and other parameters, differ by route of administration. Likewise, the potency of estradiol, and its local effects in certain tissues, most importantly the liver, differ by route of administration as well. In particular, the oral route is subject to a high first-pass effect, which results in high levels of estradiol and consequent estrogenic effects in the liver and low potency due to first-pass hepatic and intestinal metabolism into metabolites like estrone and estrogen conjugates. Conversely, this is not the case for parenteral (non-oral) routes, which bypass the intestines and liver. Different estradiol routes and dosages can achieve widely varying circulating estradiol levels (see the table below). For purposes of comparison with normal physiological circumstances, menstrual cycle circulating levels of estradiol in premenopausal women are 40 pg/mL in the early follicular phase, 250 pg/mL at the middle of the cycle, and 100 pg/mL during the mid-luteal phase. Mean integrated levels of circulating estradiol in premenopausal women across the whole menstrual cycle are in the range of 80 to 150 pg/mL, according to some sources.
The first decision of the Socialist government of José Luis Rodríguez Zapatero was to order the withdrawal of Spanish troops from Iraq, thus fulfilling what was promised during the electoral campaign, which was accompanied by a rapprochement with Germany and France. This allowed the negotiations of the Treaty of the European Constitution, which was signed in Rome in October 2004, to be unblocked. Zapatero hastened to call the ratification referendum held in February 2005, which obtained the approval of 75% of the voters but registered the highest abstention of all democracy. However, Rodríguez Zapatero was isolated internationally when the European Constitution project foundered and, above all, when Germany and France "reconciled" with the United States. Moreover, his proposal for the Alliance of Civilizations presented to the 2004 UN General Assembly as an alternative to President Bush's "war on terror" found little international backing. The Popular Party blamed its defeat in the elections on the "manipulation" of public opinion during the two days following the "11-M" attack by the PSOE and the related media. Thus, the PP implicitly questioned the legitimacy of the new government and in the sessions of the parliamentary commission that was formed to investigate the events the PP spokesmen led by Eduardo Zaplana, endorsed the 11-M conspiracy theory.
Sources: en.wikipedia.org
GSH + R• → RH + GS• → 1/2 GSSG Thiyl radicals (such as glutathionyl radicals) are themselves oxidizing species in biology, with a single-electron reduction potential sufficient for oxidation of nucleic acids, proteins and polyunsaturated lipids. Therefore, GSH itself may not be effective at direct reduction of reactive oxygen species under physiological conditions. Under oxidizing conditions, hydrogen sulfide may react with glutathione (or other electrophilic oxidized forms of glutathione) to form glutathione hydropersulfide (GS–SH), which is a superior radical-trapping antioxidant and reductant. GSH is a highly important indirect antioxidant by acting as a coenzyme for various enzymes that couple GSH-to-GSSG oxidation to the reduction of harmful oxidizing species. Such enzymes include the glutathione peroxidase family, the glutaredoxin family, the peroxiredoxin family, and others.
"Handout on Health: Back Pain". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 10 April 2017. Qaseem A, Wilt TJ, McLean RM, Forciea MA (April 2017). "Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 166 (7): 514–30. doi:10.7326/M16-2367. PMID 28192789. "Non-specific Back Pain Guidelines" (PDF). Kaiser Foundation Health Plan of Washington. 2017. Archived from the original (PDF) on 14 January 2020.
== Creationism == A Methodist from age ten, and later a fundamentalist Baptist, Gish believed that the Genesis creation narrative was historical fact. After reading the booklet Evolution, "Science Falsely So-called" in the late 1950s, Gish became persuaded that science had produced falsifiable evidence against evolutionary theory, particularly the origin of life, and that various fields of science offered corroborating evidence in support of the Genesis creation narrative. He joined the American Scientific Affiliation (ASA), an association of Christian scientists, mistakenly assuming the group supported creationism. Through his affiliation at the ASA, Gish met geneticist and creationist William J. Tinkle, who in 1961 invited Gish to join a newly formed anti-evolution caucus within the ASA. In 1971, Gish became a member of the faculty at San Diego Christian College, working in its research division before accepting a position at the Institute for Creation Research (independent since 1981). He was the author of several books and articles espousing creationism. His best-known work, Evolution: The Fossils Say No!, published in 1972, has been widely accepted by creationists as an authoritative reference. Gish initially "assigned low priority to the question of [the] age [of the Earth]". At his death on March 5, 2013, Gish held the position of Senior Vice-President Emeritus at the ICR.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.